Association between one‐time prostate‐specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30‐year prospective cohort study
Objectives To explore if there is a long‐term association between baseline prostate‐specific antigen (PSA), including free/total PSA ratio and long‐term (30‐year) risk for prostate cancer death. Subjects and methods In all, 1782 men were screened for prostate cancer through PSA analysis. Some years...
Saved in:
| Published in | BJU international Vol. 128; no. 4; pp. 490 - 496 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.10.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Objectives
To explore if there is a long‐term association between baseline prostate‐specific antigen (PSA), including free/total PSA ratio and long‐term (30‐year) risk for prostate cancer death.
Subjects and methods
In all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free to total PSA (f/t PSA). At 30‐year follow‐up, baseline PSA and f/t PSA were compared with recent data extracts from the Swedish Cause of Death Registry and Swedish Cancer Registry. PSA values and f/t PSA values were treated as continuous variables in a multivariable analysis and also stratified according to their distribution and useful clinical thresholds.
Results
Risk of death from prostate cancer after 30 years of follow‐up was significantly increased with a higher baseline PSA level, with the hazard ratio being 1.04 (95% confidence interval 1.03–1.09) per increase of one unit of PSA. Adding f/t PSA increased the model's ability to discriminate (concordance index 0.84–0.88). Men with PSA levels <1.0 ng/mL had a very low long‐term risk of prostate cancer death (1.2% risk). An f/t PSA ≥ 0.25 extended the low‐risk range to PSA < 2.0 ng/mL (1.5% risk).
Conclusion
Prostate‐specific antigen testing can be carried out less frequently or can be discontinued in men aged 55–70 years if their PSA levels are <2.0 ng/mL and the f/t PSA is ≥0.25. |
|---|---|
| AbstractList | To explore if there is a long-term association between baseline prostate-specific antigen (PSA), including free/total PSA ratio and long-term (30-year) risk for prostate cancer death.OBJECTIVESTo explore if there is a long-term association between baseline prostate-specific antigen (PSA), including free/total PSA ratio and long-term (30-year) risk for prostate cancer death.In all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free to total PSA (f/t PSA). At 30-year follow-up, baseline PSA and f/t PSA were compared with recent data extracts from the Swedish Cause of Death Registry and Swedish Cancer Registry. PSA values and f/t PSA values were treated as continuous variables in a multivariable analysis and also stratified according to their distribution and useful clinical thresholds.SUBJECTS AND METHODSIn all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free to total PSA (f/t PSA). At 30-year follow-up, baseline PSA and f/t PSA were compared with recent data extracts from the Swedish Cause of Death Registry and Swedish Cancer Registry. PSA values and f/t PSA values were treated as continuous variables in a multivariable analysis and also stratified according to their distribution and useful clinical thresholds.Risk of death from prostate cancer after 30 years of follow-up was significantly increased with a higher baseline PSA level, with the hazard ratio being 1.04 (95% confidence interval 1.03-1.09) per increase of one unit of PSA. Adding f/t PSA increased the model's ability to discriminate (concordance index 0.84-0.88). Men with PSA levels <1.0 ng/mL had a very low long-term risk of prostate cancer death (1.2% risk). An f/t PSA ≥ 0.25 extended the low-risk range to PSA < 2.0 ng/mL (1.5% risk).RESULTSRisk of death from prostate cancer after 30 years of follow-up was significantly increased with a higher baseline PSA level, with the hazard ratio being 1.04 (95% confidence interval 1.03-1.09) per increase of one unit of PSA. Adding f/t PSA increased the model's ability to discriminate (concordance index 0.84-0.88). Men with PSA levels <1.0 ng/mL had a very low long-term risk of prostate cancer death (1.2% risk). An f/t PSA ≥ 0.25 extended the low-risk range to PSA < 2.0 ng/mL (1.5% risk).Prostate-specific antigen testing can be carried out less frequently or can be discontinued in men aged 55-70 years if their PSA levels are <2.0 ng/mL and the f/t PSA is ≥0.25.CONCLUSIONProstate-specific antigen testing can be carried out less frequently or can be discontinued in men aged 55-70 years if their PSA levels are <2.0 ng/mL and the f/t PSA is ≥0.25. Objectives To explore if there is a long‐term association between baseline prostate‐specific antigen (PSA), including free/total PSA ratio and long‐term (30‐year) risk for prostate cancer death. Subjects and methods In all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free to total PSA (f/t PSA). At 30‐year follow‐up, baseline PSA and f/t PSA were compared with recent data extracts from the Swedish Cause of Death Registry and Swedish Cancer Registry. PSA values and f/t PSA values were treated as continuous variables in a multivariable analysis and also stratified according to their distribution and useful clinical thresholds. Results Risk of death from prostate cancer after 30 years of follow‐up was significantly increased with a higher baseline PSA level, with the hazard ratio being 1.04 (95% confidence interval 1.03–1.09) per increase of one unit of PSA. Adding f/t PSA increased the model's ability to discriminate (concordance index 0.84–0.88). Men with PSA levels <1.0 ng/mL had a very low long‐term risk of prostate cancer death (1.2% risk). An f/t PSA ≥ 0.25 extended the low‐risk range to PSA < 2.0 ng/mL (1.5% risk). Conclusion Prostate‐specific antigen testing can be carried out less frequently or can be discontinued in men aged 55–70 years if their PSA levels are <2.0 ng/mL and the f/t PSA is ≥0.25. ObjectivesTo explore if there is a long‐term association between baseline prostate‐specific antigen (PSA), including free/total PSA ratio and long‐term (30‐year) risk for prostate cancer death.Subjects and methodsIn all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free to total PSA (f/t PSA). At 30‐year follow‐up, baseline PSA and f/t PSA were compared with recent data extracts from the Swedish Cause of Death Registry and Swedish Cancer Registry. PSA values and f/t PSA values were treated as continuous variables in a multivariable analysis and also stratified according to their distribution and useful clinical thresholds.ResultsRisk of death from prostate cancer after 30 years of follow‐up was significantly increased with a higher baseline PSA level, with the hazard ratio being 1.04 (95% confidence interval 1.03–1.09) per increase of one unit of PSA. Adding f/t PSA increased the model's ability to discriminate (concordance index 0.84–0.88). Men with PSA levels <1.0 ng/mL had a very low long‐term risk of prostate cancer death (1.2% risk). An f/t PSA ≥ 0.25 extended the low‐risk range to PSA < 2.0 ng/mL (1.5% risk).ConclusionProstate‐specific antigen testing can be carried out less frequently or can be discontinued in men aged 55–70 years if their PSA levels are <2.0 ng/mL and the f/t PSA is ≥0.25. To explore if there is a long-term association between baseline prostate-specific antigen (PSA), including free/total PSA ratio and long-term (30-year) risk for prostate cancer death. In all, 1782 men were screened for prostate cancer through PSA analysis. Some years later, frozen plasma samples were used to calculate the ratio of free to total PSA (f/t PSA). At 30-year follow-up, baseline PSA and f/t PSA were compared with recent data extracts from the Swedish Cause of Death Registry and Swedish Cancer Registry. PSA values and f/t PSA values were treated as continuous variables in a multivariable analysis and also stratified according to their distribution and useful clinical thresholds. Risk of death from prostate cancer after 30 years of follow-up was significantly increased with a higher baseline PSA level, with the hazard ratio being 1.04 (95% confidence interval 1.03-1.09) per increase of one unit of PSA. Adding f/t PSA increased the model's ability to discriminate (concordance index 0.84-0.88). Men with PSA levels <1.0 ng/mL had a very low long-term risk of prostate cancer death (1.2% risk). An f/t PSA ≥ 0.25 extended the low-risk range to PSA < 2.0 ng/mL (1.5% risk). Prostate-specific antigen testing can be carried out less frequently or can be discontinued in men aged 55-70 years if their PSA levels are <2.0 ng/mL and the f/t PSA is ≥0.25. |
| Author | Gustafsson, Ove Lundgren, Per‐Olof Kjellman, Anders Norming, Ulf |
| Author_xml | – sequence: 1 givenname: Per‐Olof orcidid: 0000-0001-7976-6962 surname: Lundgren fullname: Lundgren, Per‐Olof email: per-olof.lundgren@sll.se organization: Karolinska Institutet and Karolinska University Hospital – sequence: 2 givenname: Anders surname: Kjellman fullname: Kjellman, Anders organization: Karolinska Institutet and Karolinska University Hospital – sequence: 3 givenname: Ulf surname: Norming fullname: Norming, Ulf organization: Karolinska Institutet and Södersjukhuset – sequence: 4 givenname: Ove surname: Gustafsson fullname: Gustafsson, Ove organization: Karolinska Institutet and Karolinska University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33811738$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:146523291$$DView record from Swedish Publication Index |
| BookMark | eNp1ks1u1DAQxy1URNuFAy-ALHFpD-nacWIn3JaK8qFKIEElbpbjTKiXfCy2wyq3PgLvwJvxJMx-9VCBD_Z4_Jv_jO05JUf90AMhzzm74Djm1XK84HnG1SNywjOZJRlnX48ONivlMTkNYckYOmT-hBwLUXCuRHFCfi9CGKwz0Q09rSCuAXqK6n_ufkXXAV35IUQTN_uwAusaZ6npo_uG2Nmnz4tzGiFEunbxljYeYB6HaFqKJ9RvRBGu70WoNb0FT7vBI-Ti9IouqGCoPYHxWwxzRPcTyeEWIRriWE9PyePGtAGe7dcZubl68-XyXXL98e37y8V1YrNUqqQQaWaZAglWVJniFciGVVnRgEgLUSjTcGMLWeSqlqU0ElSpCmlTa-qqtjkTM5LsdMMaVmOlV951xk96ME7vXd_RAp1JwUSJ_NmOx8J_jPgMunPBQtuaHoYx6DRnmIylJUf05QN0OYy-x9sgpaQSeYbTjLzYU2PVQX1fwOG7EJjvAItPFTw02rq4_bvojWs1Z3rTEBobQm8bAiPOH0QcRP_F7tXXroXp_6B-_eFmF_EXAxfJow |
| CitedBy_id | crossref_primary_10_3390_ijms24065160 crossref_primary_10_21886_2308_6424_2022_10_1_110_120 crossref_primary_10_1111_bju_15611 crossref_primary_10_3390_ijms232012415 crossref_primary_10_1016_j_exger_2023_112118 crossref_primary_10_1016_j_prnil_2024_12_001 crossref_primary_10_4111_icu_20240229 crossref_primary_10_1111_bju_16597 crossref_primary_10_1111_bju_15642 crossref_primary_10_3389_fonc_2022_985940 crossref_primary_10_1016_j_prmcm_2022_100143 |
| Cites_doi | 10.1002/ijc.25846 10.1046/j.1464-410x.2001.02143.x 10.1136/bmj.c4521 10.1016/j.eururo.2005.04.015 10.1007/s10654-017-0316-1 10.1016/j.juro.2008.11.115 10.1016/j.eururo.2015.01.009 10.1016/j.urology.2005.10.052 10.1136/bmjopen-2017-017729 10.1016/j.juro.2018.01.080 10.1002/cncr.25568 10.1016/S0022-5347(17)37041-6 10.1016/S0022-5347(17)35408-3 10.1080/21681805.2018.1508166 10.1080/00365590802078583 10.1200/JCO.2016.66.7527 10.1002/sim.4154 10.1001/jamanetworkopen.2019.19284 10.1016/j.eururo.2007.04.037 10.1001/jama.2018.3710 10.1016/j.eururo.2018.12.014 10.1016/S0140-6736(07)61602-X |
| ContentType | Journal Article |
| Copyright | 2021 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International 2021 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International. 2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International – notice: 2021 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International. – notice: 2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7X8 ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1111/bju.15417 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Calcium & Calcified Tissue Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | 496 |
| ExternalDocumentID | oai_swepub_ki_se_463039 33811738 10_1111_bju_15417 BJU15417 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Independent Order of Odd Fellows – fundername: Percy Falks Stiftelse för Forskning Beträffande Prostata‐ och Bröstcancer |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7QP 7X8 1OB ADTPV AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-c4267-8324c07e6ec3b471be6f0b48fe328387af1ac86857d696a6e79786c2cadbdc503 |
| IEDL.DBID | DR2 |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Mon Aug 25 03:26:06 EDT 2025 Fri Jul 11 07:57:34 EDT 2025 Sun Jul 13 03:55:09 EDT 2025 Mon Jul 21 05:59:51 EDT 2025 Tue Jul 01 03:50:23 EDT 2025 Thu Apr 24 22:52:24 EDT 2025 Wed Jan 22 16:27:32 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | prostate cancer screening uroonc PCSM mortality ProstateCancer prognosis prostate-specific antigen |
| Language | English |
| License | Attribution-NonCommercial 2021 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4267-8324c07e6ec3b471be6f0b48fe328387af1ac86857d696a6e79786c2cadbdc503 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7976-6962 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbju.15417 |
| PMID | 33811738 |
| PQID | 2576735467 |
| PQPubID | 1026371 |
| PageCount | 7 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_463039 proquest_miscellaneous_2508570291 proquest_journals_2576735467 pubmed_primary_33811738 crossref_citationtrail_10_1111_bju_15417 crossref_primary_10_1111_bju_15417 wiley_primary_10_1111_bju_15417_BJU15417 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2021 |
| PublicationDateYYYYMMDD | 2021-10-01 |
| PublicationDate_xml | – month: 10 year: 2021 text: October 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2021 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 68 2017; 7 2020; 3 2011; 129 1990; 79 2011; 117 2006; 67 2007; 370 2019; 75 2009; 181 2018; 200 2017; 32 1992; 148 1993; 150 2010; 341 2011; 30 2018; 52 2018; 319 2007; 52 2008; 42 2005; 48 2016; 34 2001; 87 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 Beisland HO (e_1_2_7_16_1) 1990; 79 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_2_1 Kovac E (e_1_2_7_9_1) 2020; 3 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_24_1 e_1_2_7_12_1 e_1_2_7_23_1 e_1_2_7_11_1 e_1_2_7_22_1 e_1_2_7_10_1 e_1_2_7_21_1 e_1_2_7_20_1 Young GJ (e_1_2_7_3_1) 2017; 7 35297161 - BJU Int. 2022 Mar;129(3):419 35297160 - BJU Int. 2022 Mar;129(3):418 |
| References_xml | – volume: 48 start-page: 386 issue: 3 year: 2005 end-page: 99 article-title: Use of prostate‐specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta‐analysis publication-title: Eur Urol – volume: 67 start-page: 762 issue: 4 year: 2006 end-page: 8 article-title: A meta‐analysis of the performance characteristics of the free prostate‐specific antigen test publication-title: Urology – volume: 34 start-page: 2705 issue: 23 year: 2016 end-page: 11 article-title: Baseline prostate‐specific antigen levels in midlife predict lethal prostate cancer publication-title: J Clin Oncol – volume: 200 start-page: 82 issue: 1 year: 2018 end-page: 8 article-title: Long‐term outcome of a single intervention population based prostate cancer screening study publication-title: J Urol – volume: 30 start-page: 1105 issue: 10 year: 2011 end-page: 17 article-title: On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data publication-title: Statistics Med – volume: 79 start-page: 200 issue: 4 year: 1990 end-page: 2 article-title: Neodymium‐YAG laser in the treatment of localized prostate cancer publication-title: Ann Chir Gynaecol – volume: 42 start-page: 352 issue: 4 year: 2008 end-page: 7 article-title: South‐east region prostate cancer G. Reliability of death certificates in prostate cancer patients publication-title: Scand J Urol Nephrol – volume: 341 start-page: c4521 year: 2010 article-title: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case‐control study publication-title: BMJ – volume: 52 start-page: 256 issue: 4 year: 2018 end-page: 62 article-title: Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Goteborg randomized population‐based prostate cancer screening trial publication-title: Scand J Urol – volume: 129 start-page: 1881 issue: 8 year: 2011 end-page: 8 article-title: Uptake of prostate‐specific antigen testing for early prostate cancer detection in Sweden publication-title: Int J Cancer – volume: 7 issue: 10 year: 2017 article-title: Prostate‐specific antigen (PSA) testing of men in UK general practice: a 10‐year longitudinal cohort study publication-title: BMJ Open – volume: 181 start-page: 1615 issue: 4 year: 2009 end-page: 21 article-title: 15‐year followup of a population based prostate cancer screening study publication-title: J Urol – volume: 117 start-page: 1210 issue: 6 year: 2011 end-page: 9 article-title: Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50 publication-title: Cancer – volume: 148 start-page: 1827 issue: 6 year: 1992 end-page: 31 article-title: Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men publication-title: J Urol – volume: 75 start-page: 358 issue: 3 year: 2019 end-page: 67 article-title: Guidelines for reporting of statistics for clinical research in urology publication-title: Eur Urol – volume: 32 start-page: 765 issue: 9 year: 2017 end-page: 73 article-title: The Swedish cause of death register publication-title: Eur J Epidemiol – volume: 150 start-page: 100 issue: 1 year: 1993 end-page: 5 article-title: Serum prostate specific antigen complexed to alpha 1‐antichymotrypsin as an indicator of prostate cancer publication-title: J Urol – volume: 3 issue: 1 year: 2020 article-title: Association of baseline prostate‐specific antigen level with long‐term diagnosis of clinically significant prostate cancer among patients aged 55 to 60 years: a secondary analysis of a cohort in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial publication-title: JAMA Netw Open – volume: 52 start-page: 1358 issue: 5 year: 2007 end-page: 64 article-title: hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen‐detected men within the PSA range 4–10 ng/ml publication-title: Eur Urol – volume: 370 start-page: 1453 issue: 9596 year: 2007 end-page: 7 article-title: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies publication-title: Lancet – volume: 319 start-page: 1901 issue: 18 year: 2018 end-page: 13 article-title: Screening for prostate cancer: US preventive services task force recommendation statement publication-title: JAMA – volume: 68 start-page: 207 issue: 2 year: 2015 end-page: 13 article-title: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate‐specific Antigen and a Panel of Kallikrein Markers: A Nested Case‐Control Study publication-title: Eur Urol – volume: 87 start-page: 638 issue: 7 year: 2001 end-page: 42 article-title: Variation in percentage‐free prostate‐specific antigen (PSA) with prostate volume, age and total PSA level publication-title: BJU Int – ident: e_1_2_7_2_1 doi: 10.1002/ijc.25846 – ident: e_1_2_7_17_1 doi: 10.1046/j.1464-410x.2001.02143.x – ident: e_1_2_7_24_1 doi: 10.1136/bmj.c4521 – ident: e_1_2_7_6_1 doi: 10.1016/j.eururo.2005.04.015 – ident: e_1_2_7_19_1 doi: 10.1007/s10654-017-0316-1 – ident: e_1_2_7_13_1 doi: 10.1016/j.juro.2008.11.115 – ident: e_1_2_7_11_1 doi: 10.1016/j.eururo.2015.01.009 – ident: e_1_2_7_5_1 doi: 10.1016/j.urology.2005.10.052 – volume: 7 start-page: e017729 issue: 10 year: 2017 ident: e_1_2_7_3_1 article-title: Prostate‐specific antigen (PSA) testing of men in UK general practice: a 10‐year longitudinal cohort study publication-title: BMJ Open doi: 10.1136/bmjopen-2017-017729 – ident: e_1_2_7_14_1 doi: 10.1016/j.juro.2018.01.080 – ident: e_1_2_7_7_1 doi: 10.1002/cncr.25568 – ident: e_1_2_7_15_1 doi: 10.1016/S0022-5347(17)37041-6 – ident: e_1_2_7_4_1 doi: 10.1016/S0022-5347(17)35408-3 – ident: e_1_2_7_12_1 doi: 10.1080/21681805.2018.1508166 – ident: e_1_2_7_18_1 doi: 10.1080/00365590802078583 – ident: e_1_2_7_8_1 doi: 10.1200/JCO.2016.66.7527 – ident: e_1_2_7_20_1 doi: 10.1002/sim.4154 – volume: 3 start-page: e1919284 issue: 1 year: 2020 ident: e_1_2_7_9_1 article-title: Association of baseline prostate‐specific antigen level with long‐term diagnosis of clinically significant prostate cancer among patients aged 55 to 60 years: a secondary analysis of a cohort in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.19284 – ident: e_1_2_7_10_1 doi: 10.1016/j.eururo.2007.04.037 – ident: e_1_2_7_23_1 doi: 10.1001/jama.2018.3710 – ident: e_1_2_7_22_1 doi: 10.1016/j.eururo.2018.12.014 – volume: 79 start-page: 200 issue: 4 year: 1990 ident: e_1_2_7_16_1 article-title: Neodymium‐YAG laser in the treatment of localized prostate cancer publication-title: Ann Chir Gynaecol – ident: e_1_2_7_21_1 doi: 10.1016/S0140-6736(07)61602-X – reference: 35297160 - BJU Int. 2022 Mar;129(3):418 – reference: 35297161 - BJU Int. 2022 Mar;129(3):419 |
| SSID | ssj0014665 |
| Score | 2.4104383 |
| Snippet | Objectives
To explore if there is a long‐term association between baseline prostate‐specific antigen (PSA), including free/total PSA ratio and long‐term... To explore if there is a long-term association between baseline prostate-specific antigen (PSA), including free/total PSA ratio and long-term (30-year) risk... ObjectivesTo explore if there is a long‐term association between baseline prostate‐specific antigen (PSA), including free/total PSA ratio and long‐term... |
| SourceID | swepub proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 490 |
| SubjectTerms | Aged Antigens Cohort analysis Cohort Studies Death Early Detection of Cancer - methods Humans Male Middle Aged mortality PCSM prognosis Prospective Studies Prostate cancer Prostate-Specific Antigen - blood ProstateCancer prostate‐specific antigen Prostatic Neoplasms - blood Prostatic Neoplasms - mortality Risk Assessment screening Time Factors uroonc |
| Title | Association between one‐time prostate‐specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30‐year prospective cohort study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbju.15417 https://www.ncbi.nlm.nih.gov/pubmed/33811738 https://www.proquest.com/docview/2576735467 https://www.proquest.com/docview/2508570291 http://kipublications.ki.se/Default.aspx?queryparsed=id:146523291 |
| Volume | 128 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB6VIiEu_P8EysoghMohbRI7jgOnXWBVVSqqgJV6QIpixz5Q2K222QOceIS-Q9-sT9IZx4lafiTEabPr2cSOZ-JvnJlvAJ7bRrjCZTIWWolYlKaMVZmLOC2t4oanXBna79h7L3dmYvcgP1iD130uTMcPMWy4kWX45zUZeK2PLxi5_rKibZGUMskpVosA0YeBOgofAL6MJH5iFxCnB1YhiuIZ_nl5LfoNYA7soZeBq195pjfhc9_nLuDkcGvV6i3z4xc6x_8c1C24ERApG3cqdBvW7PwOXNsL79zvwumFGWQhrIst5vbs5wkVpmdHlDeCiBW_U9omhR4xnC5i-WSb-x_HLxmi2ZbRhi9zS2u32wUCfoYtzGsfCjfDSZghLVyyb94rQA_hFRsznuC5v6NJerGQGsqotO-yZZ4f9x7Mpu8-vdmJQ2mH2CAkwHURcZxJCiut4RrXR22lS7RQznLEO6qoXVobJVVeNLKUtbQFervSZKZudGPyhN-H9TkO9SEwhU68KXJbo54Jnem6RsQldMKVS1Lnmgg2-0muTOA9p_IbX6ve_8GbXvmbHsGzQfSoI_v4k9BGrylVsPfjity2gue46kTwdGhGS6XXL_XcLlYk46sJZGUawYNOw4arcE4Jv1xF8KJTuaGF6L_DT4d4ZCshEXWUOCqvR3_vZzXZnfmDR_8u-hiuZxSz44MVN2C9Xa7sEwRdrR7BlUzsj-DqePJ2Mh15WzsHGPQvEg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIkEvvB-BAgYh1B5SkthxHMRleVRL6VYIulIvKIod59DCbrVkD3DiJ_Af-Gf8EmYcx2p5SIjTZteziR3PZL5xxt8APLSNaIs2k7HQSsSiNGWsylzEaWkVNzzlytB6x2RPjqdi5yA_WIGnw16Ynh8iLLiRZbjnNRk4LUifsHJ9uKR1kbQ4A2epojcx5794G8ij8BHgCkniJ3YCkbrnFaI8nvDX097oN4gZ-ENPQ1fne7Yvwvuh133KydHWstNb5ssvhI7_O6xLcMGDUjbqtegyrNjZFTg38a_dr8L3E5PIfGYXm8_sj6_fqDY9O6atIwha8Tvt3KTsI4YzRkSfbOPNu9EmQ0DbMVrzZe3C2sfdHDE_wxbmFBCFm3ASZkgRF-yjCwwwSHjCRowneO7PaJVOzO8OZVTdd9ExR5F7DabbL_efj2Nf3SE2iArQNSKUM0lhpTVco4vUVraJFqq1HCGPKuo2rY2SKi8aWcpa2gIDXmkyUze6MXnCr8PqDId6E5jCON4Uua1R1YTOdF0j6BI64apN0rZtItgYZrkynvqcKnB8qIYQCG965W56BA-C6HHP9_EnofVBVSpv8p8qitwKnqPjieB-aEZjpTcw9czOlyTjCgpkZRrBjV7FwlU4pz2_XEXwqNe50EIM4P6nIzyylZAIPEoclVOkv_ezerYzdQe3_l30Hpwf7092q91Xe69vw1pGKTwud3EdVrvF0t5BDNbpu87UfgI0gDDl |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NjtMwEB7tFmm1F8Q_gQUMQmg5RJvEju3AqfxUy8KuKkGlvUWxYx9gt61KeuDGI_AOvBlPwozjRrsCJE5N62maZGY639jjbwCeulZ45QuZCqNFKipbpboqRZpXTnPLc64tzXccn8jDmTg6LU-34OVmL0zPDzFMuJFnhP9rcvBl6y84ufm8pmmRXG3DFVrso3quQkyHJQQhQx9JfMVrQKAeaYWojGf46uVg9AfCHOhDLyPXEHom1-BqxIxs3Cv5Omy5-Q3YOY6r4jfh54VnzGLhFVvM3a_vP6h1PFvSzg7ElPieNlZScRDDB0o8nGx_-nH8nCHe7BhNyTK_cu6gWyAkZzjCgn2gcDuchFmykxU7D7gdMfwLNmY8w3N_Q6cJYnHzJqPmu6uOBQbbWzCbvP30-jCNzRdSi0EbIxciLZspJ53lBiOYcdJnRmjvOCISrRqfN1ZLXapWVrKRTmE-Km1hm9a0tsz4bRjN8VbvAtOYZltVugYtQZjCNA1iImEyrn2We98msL_RQm0jMzk1yDirNxkKKqwOCkvgySC67Ok4_ia0t1FlHT3ya02JleIlxoUEHg_D6Eu0QNLM3WJNMoHvv6jyBO70JjD8Cqbyea64TuBZbxPDCBF0x4--4JGrhURcUOFdBZv593XWr45m4eDe_4s-gp3pm0n94d3J-_uwW1CBTags3INRt1q7B4iQOvMweMJvXXEPXw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+one-time+prostate-specific+antigen+%28PSA%29+test+with+free%2Ftotal+PSA+ratio+and+prostate+cancer+mortality%3A+A+30-year+prospective+cohort+study&rft.jtitle=BJU+international&rft.au=Lundgren%2C+P-O&rft.au=Kjellman%2C+A&rft.au=Norming%2C+U&rft.au=Gustafsson%2C+O&rft.date=2021-10-01&rft.issn=1464-4096&rft.volume=128&rft.issue=4&rft.spage=490&rft_id=info:doi/10.1111%2Fbju.15417&rft.externalDocID=oai_swepub_ki_se_463039 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |